Redx Pharma plc - Redx announces new drug development candidate
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
("Redx" or "the Company")
RXC006, a novel, oral porcupine inhibitor, to be developed as a first-in-class treatment for the orphan disease, idiopathic pulmonary fibrosis
First-in-man studies earmarked for 2020
Pre-clinical data to be presented at the Anti-Fibrotic Drug Development summit,
RXC006 represents a novel approach to treat this debilitating and progressive disease through targeting porcupine, a component enzyme of the Wnt pathway. There is strong scientific evidence that this pathway is critically involved in the scarring process (fibrosis) in the lung that is a hallmark of IPF.1 This leads, over time, to the lungs being unable to function effectively, ultimately resulting in suffocation and death. Porcupine inhibition suppresses the release of all Wnt ligands and therefore should eliminate one of the major drivers of fibrosis in IPF. The median survival from IPF diagnosis is 3 years and the annual incidence is between 6.8-16.3/100,000 population in the
Extensive pre-clinical testing has revealed that RXC006 is very potent and highly effective at suppressing the Wnt pathway, and hence fibrosis, in vivo in the lung as well as in the liver and the kidney. Evidence shows that involvement of the Wnt pathway increases with disease severity3 and Redx believe that RXC006 may also prove effective in more severe IPF patients where there is currently no effective therapy beyond palliative care.
For further information, please contact:
| || |
T: +44 1625 469 920
| || |
| || |
T: +44 20 7894 7000
| || |
| || |
T: +44 20 3705 9330
T: +44 20 3727 1000
| || |
Redx is a
If you would like to sign up to regular alerts from
IPF is a life threatening fibrotic lung condition with diagnosed prevalence projected to increase from 119,000 (2015) to 138,000 (2025). Current treatment options are OFEV®(nintedanib) and Esbriet® (pirfenidone); both slow progression of disease by approximately 50%. Product sales in IPF are projected to increase from
Redx has invested into research to target the Wnt /ß-Catenin signalling pathway by inhibition of the upstream porcupine enzyme and has built considerable knowledge and expertise in this scientific area. Our most advanced porcupine inhibitor, RXC004, is currently being investigated clinically for the treatment of a range of cancers. RXC006 is a potent porcupine inhibitor protected by discrete Intellectual Property and has a predicted human PK profile which will allow flexibility in dosing regimens to balance efficacy with potential side effects. RXC006 is the first porcupine inhibitor aimed at treating IPF.
1. Newman DR, Sills WS, Hanrahan K, Ziegler A, Tidd KM, Cook E, Sannes PL.
Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-β and WNT7B in Human Lung Fibroblasts. J Histochem Cytochem. 2016 Feb;64(2):99-111.
2. Global Data Opportunity Analyser 2015, based on 7 major markets
3. Meuten T, Hickey A, Franklin K, Grossi B, Tobias J, Newman DR,
This information is provided by RNS, the news service of the
Quick facts: Redx Pharma PLC
Market Cap: £23.75 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE